Lotus Eye Hospital And Institute Limited has filed its quarterly compliance certificate with stock exchanges and depositories, confirming adherence to SEBI regulations for securities dematerialization during Q4FY26.

Regulatory Compliance Certificate

The company submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, dated April 06, 2026. This quarterly filing covers the period ended March 31, 2026, ensuring transparency in the dematerialization process.

Dematerialization Process Confirmation

The certificate confirms that securities received for dematerialization have been properly processed according to regulatory requirements. Key compliance aspects include:

• Securities mutilated and cancelled after due verification
• Depository name substituted in company records as registered owner
• Process completed within 15 days of certificate receipt
• Details furnished to stock exchanges as required

Stock Exchange Listing Compliance

Lotus Eye Hospital confirmed that dematerialized securities remain listed on the same stock exchanges where earlier issued securities are traded. This ensures continuity of trading and maintains investor access to the company's shares.

Registrar Verification

MUFG Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, provided certification supporting the compliance filing. The registrar confirmed proper handling of securities received from depository participants during the quarter, with appropriate acceptance or rejection procedures followed.

The filing was signed by Prathish S, Company Secretary & Compliance Officer, demonstrating the company's commitment to maintaining regulatory standards and protecting investor interests through proper dematerialization procedures.

Lotus Eye Hospital and Institute Limited has decided against proceeding with its voluntary delisting proposal from the National Stock Exchange of India Limited (NSE). The board of directors, in their meeting held on March 17, 2026, formally rejected the delisting proposal after considering current market conditions, liquidity factors, and the need to ensure continued investor convenience and flexibility.

Board Meeting Outcome

The healthcare company's board meeting commenced at 04:30 PM and concluded at 05:00 PM on March 17, 2026. The decision was communicated to both stock exchanges in compliance with Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations 2015.

Rationale Behind Decision

The board cited several key factors in their decision-making process. Current market conditions played a significant role, along with liquidity considerations that could impact shareholder value. The company emphasized the importance of maintaining investor convenience and flexibility through continued dual exchange presence.

Continued Dual Exchange Presence

With this decision, Lotus Eye Hospital and Institute Limited will maintain its listing status on both major Indian stock exchanges. The company's equity shares will continue to be available for trading, providing investors with multiple avenues for transactions.

Corporate Operations

Lotus Eye Hospital and Institute Limited operates an extensive network of eye care facilities across South India. The company maintains locations in Coimbatore, Salem, Tirupur, Mettupalayam, Kochi, and Karur, positioning itself as a significant player in specialized eye care services across these regional markets. The company's registered office is located at 770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore, with CIN No. L85110TZ1997PLC007783.